Brigitta C. Brott, MD; William B. Hillegass, MD, MPH
What is the relative efficacy of dual antiplatelet therapy (DAPT) given for 24 months compared with 6 months after coronary stent implantation?
Randomized controlled trial (RCT) (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study [PRODIGY]). ClinicalTrials.gov NCT00611286.
Unclear allocation concealment.*
Blinded* (event adjudication committee).
3 referral centers in Italy.
1970 patients ≥ 18 years of age (mean age 68 y, 77% men) who had chronic, stable coronary artery disease or an acute coronary syndrome; ≥ 1 lesion with ≥ 50% diameter stenosis in a vessel ≥ 2.25 mm in diameter that was suitable for coronary stent implantation; and elective, urgent, or emergent coronary angioplasty with 1 of 4 randomly assigned types of stent (bare metal or everolimus-, paclitaxel-, or zotarolimus-eluting) 30 days before DAPT randomization. Exclusion criteria included planned surgery within 24 months unless DAPT could be continued, major surgery within 15 days, history of bleeding diathesis, active bleeding or stroke in the past 6 months, expected need for oral anticoagulation therapy, pregnancy, or life expectancy < 24 months.
DAPT using oral clopidogrel, loading dose of 300 or 600 mg and then 75 mg/d, plus aspirin, loading dose of 160 to 325 mg orally or IV 500 mg and then 80 to 160 mg/d orally for 24 months (n = 987); or for 6 months followed by aspirin alone (n = 983).
Primary composite endpoint (all-cause mortality, nonfatal myocardial infarction, or cerebrovascular accident). Other outcomes included components of the composite endpoint, stent thrombosis, and bleeding. 1700 patients were needed to detect a 40% relative reduction in the primary endpoint at 2 years from 8% in the 6-month group (80% power, 2-sided α = 0.05).
99.6% (intention-to-treat analysis).
The main results are in the Table.
24-month dual antiplatelet therapy after stent implantation increased bleeding and did not improve a composite of mortality, myocardial infarction, and cerebrovascular accident more than 6-month therapy.
24 mo vs 6 mo of dual antiplatelet therapy after coronary stent implantation†
†Abbreviations defined in Glossary. RRI, RRR, NNH, and CI calculated from hazard ratios and event rates in article.
‡All-cause mortality (6.6% vs 6.6%, P = 0.98), myocardial infarction (4.0% vs 4.2%, P = 0.80), and cerebrovascular accident (2.1% vs 1.4%, P = 0.17).
§Bleeding Academic Research Consortium classification type 5, 3, or 2.
Brott BC, Hillegass WB. 24- and 6-month dual antiplatelet therapy after coronary stenting did not differ for clinical outcomes. Ann Intern Med. ;157:JC2–9. doi: 10.7326/0003-4819-157-4-201208210-02009
Download citation file:
Published: Ann Intern Med. 2012;157(4):JC2-9.
Cardiology, Coronary Heart Disease, Percutaneous Coronary Intervention.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use